{"id":1425,"date":"2026-10-02T22:42:20","date_gmt":"2026-10-02T14:42:20","guid":{"rendered":"http:\/\/www.puriactives.com\/en\/?p=1425"},"modified":"2026-10-02T22:42:20","modified_gmt":"2026-10-02T14:42:20","slug":"nanoactive-oleonia","status":"publish","type":"post","link":"http:\/\/www.puriactives.com\/en\/?p=1425","title":{"rendered":"NanoActive OleoNia™"},"content":{"rendered":"

01 \u00b7 THE STARTING POINT<\/p>\n

The niacinamide paradox<\/h2>\n

Powerful biology \u2014 yet inseparable from the water phase.<\/b><\/p>\n

Niacinamide \u2014 the amide form of vitamin B3 \u2014 is one of the best-documented multifunctional cosmetic actives, driving epidermal energy metabolism as a precursor of the NAD+\/NADP+ coenzymes. Its physicochemical nature, however, makes it extremely hydrophilic:<\/p>\n

\u00b7 Readily soluble in water, almost insoluble in non-polar oils (logP\u2248\u22120.4)<\/p>\n

\u00b7 No molecular affinity for lipid phases \u2014 whenever water is present, it partitions into the water phase<\/p>\n

\u00b7 Once deprived of an aqueous environment, it re-crystallizes<\/p>\n

\u00b7 Traditional formulas must therefore carry a water phase or solubilizers<\/p>\n

Physicochemical data: PubChem CID 936 (Niacinamide).<\/p>\n

Formats that conventional niacinamide struggles to enter<\/b><\/p>\n

Facial oil serums & oil essences\u3000\u00b7\u3000Anhydrous concentrates & balms\u3000\u00b7\u3000Lipid-rich barrier-repair formulas\u3000\u00b7\u3000Oil-continuous emulsions\u3000\u00b7\u3000Functional cleansing oils\u3000\u00b7\u3000Premium scalp & hair oils<\/p>\n

The limitation is not biological \u2014 it is a delivery-engineering problem.<\/b><\/p>\n

02 \u00b7 MARKET CONTEXT<\/p>\n

The rise of active oil-based beauty<\/h2>\n

Oil-based skincare is moving beyond simple emollience and occlusion. Barrier science, anhydrous formats and the \u201cskinification\u201d of scalp care are redefining what lipid-based products are expected to deliver.<\/p>\n

01Barrier-first skincare<\/b> \u2014 lipid replenishment becomes a core claim<\/p>\n

02The facial-oil renaissance<\/b> \u2014 from finishing step to efficacy step<\/p>\n

03Scalp & hair \u201cskinification\u201d<\/b> \u2014 facial-grade actives move to the scalp<\/p>\n

04Anhydrous formulation<\/b> \u2014 concentrated, minimalist architectures<\/p>\n

05Premium sensorial textures<\/b> \u2014 lipid richness as a signifier of efficacy<\/p>\n

THE EMERGING PRODUCT ARCHITECTURE<\/b><\/p>\n

Lipid base\u3000\uff0b\u3000functional actives\u3000\uff0b\u3000advanced delivery technology<\/b><\/p>\n

A new generation of oil-based skin, scalp and hair care.<\/p>\n

The long-missing link \u2014 a water-soluble active that can work in the oil phase.<\/b><\/p>\n

PURIPHARM \u00b7 PRODUCT LAUNCH<\/p>\n

A water-soluble active \u2014 new possibilities in the oil phase.<\/p>\n

NanoActive OleoNia™<\/h2>\n

An oil-compatible niacinamide delivery system: through a lipid-associated form, it re-engineers how a classic water-soluble active exists \u2014 allowing facial oil serums, anhydrous concentrates, balms and oil-rich scalp care to carry niacinamide biology for the first time.<\/p>\n

<\/p>\n

Nano-lipid vesicle structure \u2014 the delivery core of NanoActive OleoNia™.<\/p>\n

INCI name<\/b>\u3000Niacinamide<\/p>\n

Technology platform<\/b>\u3000PURISOME\u00ae FlexVes™ liposome technology<\/p>\n

Product line<\/b>\u3000NanoActive™<\/p>\n

03 \u00b7 THE TECHNOLOGY<\/p>\n

From water-soluble to oil-compatible<\/h2>\n

Constraints of the conventional route<\/b><\/p>\n

\u00b7 Hydrophilic molecules dissolve only where a water phase exists<\/p>\n

\u00b7 In anhydrous oils they persist as undissolved crystalline solid<\/p>\n

\u00b7 Phase separation and uneven distribution follow<\/p>\n

\u00b7 No inherent affinity for the lipid environment of skin or formula<\/p>\n

The OLEONIA™ approach<\/b><\/p>\n

\u00b7 Skin-affine phospholipids build an amphiphilic vesicle structure<\/p>\n

\u00b7 The hydrophilic active is compartmentalized inside the vesicle core<\/p>\n

\u00b7 A lipid-compatible outer interface allows dispersion in the oil phase<\/p>\n

\u00b7 Uniform incorporation in oil-continuous systems<\/p>\n

<\/p>\n

Schematic: the hydrophilic active resides inside a lipid-assembled carrier, turning a water-dependent molecule into an oil-dispersible system.<\/p>\n

03 \u00b7 THE TECHNOLOGY<\/p>\n

Vesicle architecture \u2014 PURISOME\u00ae FlexVes™ technology<\/h2>\n

<\/p>\n

Phospholipid bilayer vesicle (aqueous core) \u00b7 schematic. Image: PuriPharm technical library.<\/p>\n

1. Amphiphilic bilayer membrane.<\/b>Skin-affine phospholipids self-assemble into a closed bilayer, following the same organizing principle as epidermal barrier lipids.<\/p>\n

2. Active compartmentalization.<\/b>Hydrophilic niacinamide is located in the vesicle core \u2014 physically separated from the surrounding oil-continuous phase.<\/p>\n

3. Lipid-compatible outer interface.<\/b>The outer membrane presents a non-polar surface, letting the carrier disperse uniformly in oils and lipid-rich bases.<\/p>\n

4. Flexible-vesicle engineering.<\/b>The FlexVes™ membrane design optimizes vesicle deformability and stratum-corneum affinity \u2014 properties the literature links to enhanced skin deposition.<\/p>\n

FOUR PLATFORM FUNCTIONS<\/b><\/p>\n

Active protection\u3000\u2192\u3000enhanced skin deposition\u3000\u2192\u3000sustained availability\u3000\u2192\u3000formula & sensory compatibility<\/p>\n

Honeywell-Nguyen PL, Bouwstra JA. Drug Discov Today Technol. 2005;2(1):67\u201374. \u00b7 Bouwstra JA, Honeywell-Nguyen PL. Adv Drug Deliv Rev. 2002;54(Suppl 1):S41\u2013S55.<\/p>\n

03 \u00b7 THE TECHNOLOGY<\/p>\n

Core technical benefits \u2014 three pillars<\/h2>\n

01Expanded formulation freedom<\/b><\/p>\n

\u00b7 Facial oil serums, oil essences and lipid concentrates<\/p>\n

\u00b7 Anhydrous balms and active concentrates<\/p>\n

\u00b7 Oil-continuous and lipid-rich emulsions<\/p>\n

\u00b7 Premium oil-based scalp and hair formats<\/p>\n

02Enhanced delivery potential<\/b><\/p>\n

\u00b7 Vesicle lipids show affinity for stratum-corneum lipid domains<\/p>\n

\u00b7 Supports active deposition and local retention<\/p>\n

\u00b7 The follicular pathway offers a sustained-release reservoir<\/p>\n

03Improved active stability<\/b><\/p>\n

\u00b7 Compartmentalization isolates the active from the continuous phase<\/p>\n

\u00b7 Less direct contact with reactive co-ingredients<\/p>\n

\u00b7 Uniform distribution \u2014 no crystallization in low-water systems<\/p>\n

Delivery and stability advantages are based on published vesicle science (platform-level evidence). This presentation claims no product-specific performance data; NanoActive OleoNia™ experimental data are provided in the product’s technical documentation.<\/p>\n

03 \u00b7 THE TECHNOLOGY<\/p>\n

Expanded formulation freedom<\/h2>\n

Formats once impractical for water-soluble niacinamide become routine formulation choices.<\/p>\n\n\n\n\n\n\n\n\n
Format<\/th>\nConventional niacinamide<\/th>\nNanoActive OleoNia™<\/th>\n<\/tr>\n
Facial oil serums & oil essences<\/td>\nInsoluble; re-crystallizes in the oil phase<\/td>\nOil-dispersible active system, uniformly incorporated<\/td>\n<\/tr>\n
Anhydrous concentrates & balms<\/td>\nNo water phase to dissolve the active<\/td>\nStably compartmentalized in the lipid base<\/td>\n<\/tr>\n
Oil-continuous & lipid-rich emulsions<\/td>\nConfined to a minimal inner water phase<\/td>\nPositioned within the formula’s lipid domains<\/td>\n<\/tr>\n
Functional cleansing oils<\/td>\nIncompatible with anhydrous rinse-off bases<\/td>\nGives cleansing oils an efficacy positioning<\/td>\n<\/tr>\n
Scalp & hair oils<\/td>\nAqueous actives incompatible with oil carriers<\/td>\nOil-based delivery to the scalp and follicular environment<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Formulation statements describe the platform’s delivery principle; dosage and processing guidance are given in the product’s technical documentation.<\/p>\n

04 \u00b7 ACTIVE BIOLOGY<\/p>\n

Niacinamide biology \u2014 one molecule, five pathways<\/h2>\n

Niacinamide<\/b> \u2014 precursor of the NAD+\/NADP+ coenzymes \u2014 the \u201cmetabolic currency\u201d driving epidermal energy production, repair and differentiation.<\/p>\n

Skin barrier<\/b> \u2014 promotes ceramide and stratum-corneum lipid biosynthesis; reduces transepidermal water loss.<\/p>\n

Tanno et al. Br J Dermatol. 2000 \u00b7 Soma et al. Int J Dermatol. 2005<\/p>\n

Skin tone & pigmentation<\/b> \u2014 acts downstream of tyrosinase, inhibiting melanosome transfer from melanocytes to keratinocytes.<\/p>\n

Hakozaki et al. Br J Dermatol. 2002<\/p>\n

Skin aging<\/b> \u2014 supports cellular energy metabolism; improves elasticity, fine lines and sallowness in clinical testing.<\/p>\n

Bissett et al. Dermatol Surg. 2005<\/p>\n

Sebum & pores<\/b> \u2014 reduces facial sebum production; improves oily skin and pore appearance.<\/p>\n

Draelos et al. J Cosmet Laser Ther. 2006<\/p>\n

Inflammation<\/b> \u2014 non-antibiotic anti-inflammatory activity; soothes visible redness and erythema.<\/p>\n

Shalita et al. Int J Dermatol. 1995 \u00b7 Bissett et al. 2004<\/p>\n

Mechanistic reviews: Wohlrab J, Kreft D. Skin Pharmacol Physiol. 2014;27(6):311\u2013315. \u00b7 Boo YC. Antioxidants. 2021;10(8):1315.<\/p>\n

04 \u00b7 ACTIVE BIOLOGY<\/p>\n

Skin barrier \u2014 rebuilding the lipid \u201cmortar\u201d<\/h2>\n

As an NAD+\/NADP+ precursor, niacinamide powers keratinocyte energy metabolism and epidermal differentiation \u2014 the engine of barrier-lipid synthesis.<\/p>\n

Ceramide biosynthesis.<\/b>Niacinamide promotes de novo synthesis of ceramides and other stratum-corneum lipids in human keratinocytes, improving epidermal permeability-barrier function.<\/p>\n

Less water loss.<\/b>Topical 2% niacinamide reduced transepidermal water loss (TEWL) in atopic dry skin, outperforming a white-petrolatum control.<\/p>\n

Delivery synergy.<\/b>The lipid carrier echoes the barrier’s own chemistry \u2014 ceramides, free fatty acids and cholesterol arranged in lamellae.<\/p>\n

<\/p>\n

Tanno O et al. Br J Dermatol. 2000;143(3):524\u2013531. \u00b7 Soma Y et al. Int J Dermatol. 2005;44(3):197\u2013202. \u00b7 Brick-and-mortar schematic: PuriPharm.<\/p>\n

An active that builds barrier lipids \u2014 delivered in a carrier built from barrier-like lipids.<\/b><\/p>\n

04 \u00b7 ACTIVE BIOLOGY<\/p>\n

Brightening \u2014 blocking melanosome transfer<\/h2>\n

A downstream mechanism.<\/b>Niacinamide does not inhibit tyrosinase; it acts on pigment distribution \u2014 the transfer of melanosomes from melanocytes to keratinocytes. In melanocyte\u2013keratinocyte co-culture models, melanosome transfer was inhibited by 35\u201368%<\/b>.<\/p>\n

Reversible and cell-safe.<\/b>The inhibition is reversible and non-cytotoxic \u2014 physiological tone modulation, not melanocyte toxicity.<\/p>\n

Clinically visible.<\/b>After 4 weeks of use, hyperpigmentation was significantly reduced and skin brightness improved versus vehicle control.<\/p>\n

Hakozaki T et al. Br J Dermatol. 2002;147(1):20\u201331. \u00b7 Greatens A et al. Exp Dermatol. 2005;14(7):498\u2013508.<\/p>\n

Split-face randomized controlled trial in melasma (n = 27, 8 weeks)<\/b><\/p>\n

<\/p>\n

Navarrete-Sol\u00eds J et al. Dermatol Res Pract. 2011;2011:379173. Depigmenting efficacy comparable to hydroquinone, with fewer adverse effects.<\/p>\n

Tone correction that respects melanocyte biology.<\/b><\/p>\n

04 \u00b7 ACTIVE BIOLOGY<\/p>\n

Anti-aging \u2014 energy, elasticity, even tone<\/h2>\n

The key aging study<\/b><\/p>\n

Design.<\/b>Double-blind, left\u2013right randomized split-face trial; 50 women with clinical signs of photoaging; 5% niacinamide versus vehicle, twice daily for 12 weeks; imaging and instrumental measurements every 4 weeks.<\/p>\n

Mechanistic basis.<\/b>NAD+\/NADP+ coenzymes sustain cellular energy and repair; antioxidant defense counters the protein glycation linked to sallow tone; epidermal renewal is supported for refined texture.<\/p>\n

Endpoints significantly improved<\/b><\/p>\n

Fine lines & wrinkles\u3000\u00b7\u3000hyperpigmented spots\u3000\u00b7\u3000red blotchiness\u3000\u00b7\u3000skin sallowness\u3000\u00b7\u3000elasticity (cutometry)<\/p>\n

All endpoints significant versus vehicle control.<\/p>\n

Bissett DL et al. Dermatol Surg. 2005;31(Suppl 1):860\u2013865. \u00b7 Bissett DL et al. Int J Cosmet Sci. 2004;26(5):231\u2013238.<\/p>\n

One gentle active improving five signs of facial aging.<\/b><\/p>\n

04 \u00b7 ACTIVE BIOLOGY<\/p>\n

Sebum, pores and acne-prone skin<\/h2>\n

Sebum regulation.<\/b>2% niacinamide significantly lowered sebum excretion rate after 2\u20134 weeks (Japanese cohort) and reduced skin-surface sebum after 6 weeks (Caucasian cohort).<\/p>\n

Pore appearance.<\/b>Less sebum output means less follicular distension \u2014 the mechanical driver of enlarged pores.<\/p>\n

Acne-prone skin.<\/b>4% niacinamide gel showed anti-inflammatory efficacy comparable to 1% clindamycin gel in moderate inflammatory acne \u2014 without antibiotic-resistance concerns.<\/p>\n

Draelos ZD et al. J Cosmet Laser Ther. 2006;8(2):96\u2013101. \u00b7 Shalita AR et al. Int J Dermatol. 1995;34(6):434\u2013437.<\/p>\n

Double-blind randomized controlled trial in inflammatory acne (n = 76, 8 weeks)<\/b><\/p>\n

<\/p>\n

Shalita AR et al. Int J Dermatol. 1995;34(6):434\u2013437. No statistically significant difference between groups \u2014 equivalent efficacy.<\/p>\n

Oil control and soothing \u2014 without the antibiotic route.<\/b><\/p>\n

04 \u00b7 ACTIVE BIOLOGY<\/p>\n

Soothing and skin resilience<\/h2>\n

Barrier improvement and anti-inflammatory activity converge here \u2014 niacinamide matters as much for reactive, redness-prone skin as for aging or oily skin.<\/p>\n

Red blotchiness<\/b> \u2014 after 12 weeks of topical 5% niacinamide, facial red blotchiness was significantly reduced.<\/p>\n

Bissett et al. Dermatol Surg. 2005<\/p>\n

Rosacea-prone skin<\/b> \u2014 a niacinamide-containing facial moisturizer improved barrier function and clinical signs in these subjects.<\/p>\n

Draelos et al. Cutis. 2005;76(2):135\u2013141<\/p>\n

Inflammatory-cell infiltrate<\/b> \u2014 topical 4% niacinamide reduced mast-cell infiltrate and improved solar elastosis in melasma-skin histology.<\/p>\n

Navarrete-Sol\u00eds et al. Dermatol Res Pract. 2011<\/p>\n

Stress signaling<\/b> \u2014 mitigates environment-induced, senescence-associated inflammatory signaling in epidermal keratinocytes.<\/p>\n

Bierman et al. Int J Cosmet Sci. 2020;42(5):501\u2013511<\/p>\n

Oxidative defense<\/b> \u2014 supports endogenous antioxidant capacity via NADPH-linked redox pathways.<\/p>\n

Boo YC. Antioxidants. 2021;10(8):1315<\/p>\n

05 \u00b7 CLINICAL EVIDENCE<\/p>\n

Human clinical evidence for niacinamide<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Study<\/th>\nDesign<\/th>\nDose & duration<\/th>\nKey results<\/th>\n<\/tr>\n
Bissett 2005<\/td>\nSplit-face RCT, vehicle-controlled (n = 50)<\/td>\n5%, 12 weeks<\/td>\nFine lines, elasticity, spots, erythema and sallowness all improved<\/td>\n<\/tr>\n
Bissett 2004<\/td>\nRCT, vehicle-controlled<\/td>\n5%, 12 weeks<\/td>\nYellowing, wrinkles, red blotchiness and spots reduced<\/td>\n<\/tr>\n
Hakozaki 2002<\/td>\nVehicle-controlled clinical + co-culture study<\/td>\n5%, 4\u20138 weeks<\/td>\nPigmentation reduced; skin brightness increased<\/td>\n<\/tr>\n
Navarrete-Sol\u00eds 2011<\/td>\nSplit-face RCT in melasma (n = 27)<\/td>\n4% vs 4% hydroquinone, 8 weeks<\/td>\nComparable depigmentation; fewer adverse effects (18% vs 29%)<\/td>\n<\/tr>\n
Draelos 2006<\/td>\nTwo controlled cohorts (Japanese \/ Caucasian)<\/td>\n2%, 4\u20136 weeks<\/td>\nSebum excretion rate \/ surface sebum levels reduced<\/td>\n<\/tr>\n
Shalita 1995<\/td>\nDouble-blind RCT in inflammatory acne (n = 76)<\/td>\n4% gel vs 1% clindamycin, 8 weeks<\/td>\nComparable improvement; lesion count \u221260% vs \u221243%<\/td>\n<\/tr>\n
Soma 2005<\/td>\nControlled study, atopic dry skin<\/td>\n2%, 4\u20138 weeks<\/td>\nTEWL reduced; barrier function improved<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Full citations on the references page. RCT = randomized controlled trial; TEWL = transepidermal water loss.<\/p>\n

06 \u00b7 DELIVERY SCIENCE<\/p>\n

Why lipid delivery matters<\/h2>\n

<\/p>\n

Skin cross-sections under confocal laser scanning microscopy: smaller lipid carriers (a \u2192 c) show progressively deeper skin distribution. Image: PuriPharm technical library.<\/p>\n

A note on the evidence<\/b><\/p>\n

This page presents platform-level vesicle literature \u2014 the delivery rationale behind the engineering of NanoActive OleoNia™, not product-specific measurements.<\/p>\n

Vesicle\u2013skin interaction<\/b> \u2014 phospholipid vesicles adsorb onto and intermix with stratum-corneum lipid domains, promoting intimate carrier\u2013skin contact.<\/p>\n

Bouwstra JA, Honeywell-Nguyen PL. Adv Drug Deliv Rev. 2002;54(Suppl 1):S41\u2013S55<\/p>\n

Size determines depth<\/b> \u2014 liposome particle size directly influences dermal delivery depth; smaller vesicles deposit their payload into deeper skin layers.<\/p>\n

Verma DD et al. Int J Pharm. 2003;258(1\u20132):141\u2013151<\/p>\n

The follicular reservoir<\/b> \u2014 particulate carriers preferentially accumulate in hair follicles, persisting far longer than on the skin surface and extending local availability.<\/p>\n

Lademann J et al. Eur J Pharm Biopharm. 2007;66(2):159\u2013164<\/p>\n

Delivery engineering turns a soluble molecule into a depositable active.<\/b><\/p>\n

06 \u00b7 DELIVERY SCIENCE<\/p>\n

Stability and formulation advantages<\/h2>\n

The fragility of free niacinamide<\/b><\/p>\n

\u00b7 Amide hydrolysis: converts to nicotinic acid under acidic pH and heat \u2014 causing transient flushing and stinging<\/p>\n

\u00b7 Direct, unprotected contact with reactive co-ingredients in the water phase<\/p>\n

\u00b7 Crystallization and local concentration gradients in low-water systems<\/p>\n

The engineered response<\/b><\/p>\n

\u00b7 A compartmentalized core isolates the active from the continuous phase<\/p>\n

\u00b7 The lipid microenvironment buffers interfacial pH exposure at the molecular scale<\/p>\n

\u00b7 Uniform dispersion eliminates crystallization pathways<\/p>\n

\u00b7 A structural barrier against oxidation and interfacial stress during storage<\/p>\n

<\/p>\n

The occlusive effect.<\/b>Fine lipid carriers form a closely adherent film on the skin surface, reducing evaporative water loss and supporting stratum-corneum hydration \u2014 a further formulation-level delivery advantage. Image: PuriPharm technical library.<\/p>\n

Gehring W. J Cosmet Dermatol. 2004;3(2):88\u201393. \u00b7 Mechanistic review: Boo YC. Antioxidants. 2021;10(8):1315.<\/p>\n

07 \u00b7 FORMULATION CONCEPT<\/p>\n

From \u201cpassive oils\u201d to \u201cactive lipid systems\u201d<\/h2>\n

<\/p>\n

08 \u00b7 SCALP & HAIR<\/p>\n

Scalp and hair \u2014 niacinamide beyond the face<\/h2>\n

Scalp is skin.<\/b>Barrier-lipid synthesis, sebum dynamics and oxidative stress follow the same biology as facial skin \u2014 exactly what niacinamide targets.<\/p>\n

Follicular targeting.<\/b>Particulate carriers preferentially deposit in hair follicles and persist as long-lived reservoirs \u2014 a natural entry route for oil-based scalp products.<\/p>\n

Follicle-cell evidence.<\/b>In cultured human dermal papilla cells, niacinamide lowered oxidative-stress markers and down-regulated DKK-1, a signal associated with follicle regression (in vitro).<\/p>\n

Honest evidence positioning.<\/b>Facial benefits are clinically established; scalp-specific benefits are mechanistic and still emerging \u2014 a credible basis for \u201cbarrier-first\u201d scalp care, not a hair-growth claim.<\/p>\n

Size-dependent follicular deposition of particulate carriers<\/b><\/p>\n

<\/p>\n

The follicular pathway to the perifollicular environment<\/b><\/p>\n

<\/p>\n

Images \u2014 PuriPharm technical library.<\/p>\n

Suitable formats<\/b><\/p>\n

Scalp serum oils \u00b7 pre-wash oil treatments \u00b7 leave-on scalp essences \u00b7 hair oils \u00b7 conditioning concentrates \u00b7 overnight scalp care<\/p>\n

Lademann J et al. Eur J Pharm Biopharm. 2007;66(2):159\u2013164. \u00b7 Choi YH et al. Clin Cosmet Investig Dermatol. 2021;14:1519\u20131528.<\/p>\n

09 \u00b7 APPLICATION CONCEPTS<\/p>\n

Formulation opportunities<\/h2>\n

Skin care<\/b><\/p>\n

\u00b7 Facial oil serums \u2014 the hero format: pure oil bases carrying niacinamide biology<\/p>\n

\u00b7 Oil serums \/ bi-phase serums \u2014 lipid essences with an efficacy positioning<\/p>\n

\u00b7 Anhydrous active concentrates \u2014 minimalist water-free architectures<\/p>\n

\u00b7 Nourishing balms & overnight lipid treatments \u2014 intensified barrier care<\/p>\n

\u00b7 Barrier-repair & rich anti-aging creams \u2014 lipid-rich emulsion systems<\/p>\n

\u00b7 Brightening oil serums \u2014 tone correction in premium sensory bases<\/p>\n

\u00b7 Eye-area lipid serums \u00b7 functional cleansing oils \u2014 delicate-zone and rinse-off concepts<\/p>\n

Scalp & hair<\/b><\/p>\n

\u00b7 Scalp serum oils \u2014 follicle-targeted, barrier-first scalp care<\/p>\n

\u00b7 Pre-wash oil treatments \u2014 a barrier primer before shampooing<\/p>\n

\u00b7 Leave-on scalp essences \u2014 sustained follicular contact<\/p>\n

\u00b7 Hair oils \u2014 shine products with a scalp-care positioning<\/p>\n

\u00b7 Anti-aging scalp concentrates \u2014 an oxidative-stress defense story<\/p>\n

\u00b7 Overnight scalp treatments \u2014 long-contact reservoir strategy<\/p>\n

Concept-level positioning; dosage, processing and compatibility guidance are given in the product’s technical documentation.<\/p>\n

10 \u00b7 DIFFERENTIATION<\/p>\n

Conventional niacinamide vs NanoActive OleoNia™<\/h2>\n\n\n\n\n\n\n\n\n\n
Dimension<\/th>\nConventional niacinamide<\/th>\nNanoActive OleoNia™<\/th>\n<\/tr>\n
Form in formula<\/td>\nDissolved only in the water phase<\/td>\nLipid-associated vesicular dispersion<\/td>\n<\/tr>\n
Anhydrous suitability<\/td>\nUnsuitable \u2014 re-crystallizes without water<\/td>\nDesigned for anhydrous systems<\/td>\n<\/tr>\n
Oil compatibility<\/td>\nIncompatible without solubilizers or emulsification<\/td>\nIncorporates uniformly into the oil phase<\/td>\n<\/tr>\n
Deposition behavior<\/td>\nSurface delivery dependent on hydration<\/td>\nVesicle-supported deposition; follicular reservoir pathway<\/td>\n<\/tr>\n
Stability strategy<\/td>\nRelies on bulk-solution pH and temperature control<\/td>\nCompartmental isolation shields the active from the base<\/td>\n<\/tr>\n
Positioning<\/td>\nCommodity water-phase active<\/td>\nPremium delivery-system ingredient<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Deposition and stability characteristics reflect platform-level vesicle-delivery literature, not product-specific comparative testing.<\/p>\n

PURIPHARM \u00b7 KEY TAKEAWAYS<\/p>\n

A new formulation dimension for niacinamide<\/h2>\n

The technology spans<\/b><\/p>\n

Niacinamide biology\u3000+\u3000lipid-based formulation\u3000+\u3000advanced delivery science<\/p>\n

And thereby delivers<\/b><\/p>\n

\u00b7 Broader formulation freedom \u2014 oil serums, anhydrous concentrates, balms, oil-rich scalp care<\/p>\n

\u00b7 Greater delivery potential \u2014 vesicle\u2013skin affinity, deposition, follicular reservoir<\/p>\n

\u00b7 Better formulation stability \u2014 compartmentalized, uniform, crystallization-free<\/p>\n

\u00b7 A new generation of oil-based skin and scalp care \u2014 from passive oils to active lipid systems<\/p>\n

NanoActive OleoNia™ \u00b7 PURISOME\u00ae FlexVes™ liposome technologyPuriPharm Co. Ltd. \u00b7 www.puriactives.com<\/p>\n

11 \u00b7 REFERENCES<\/p>\n

References<\/h2>\n

1. Tanno O, Ota Y, Kitamura N, Katsube T, Inoue S. Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br J Dermatol. 2000;143(3):524\u2013531.<\/p>\n

2. Hakozaki T, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147(1):20\u201331.<\/p>\n

3. Greatens A, et al. Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible. Exp Dermatol. 2005;14(7):498\u2013508.<\/p>\n

4. Bissett DL, Miyamoto K, Sun P, Li J, Berge CA. Topical niacinamide reduces yellowing, wrinkling, red blotchiness, and hyperpigmented spots in aging facial skin. Int J Cosmet Sci. 2004;26(5):231\u2013238.<\/p>\n

5. Bissett DL, Oblong JE, Berge CA. Niacinamide: a B vitamin that improves aging facial skin appearance. Dermatol Surg. 2005;31(Suppl 1):860\u2013865.<\/p>\n

6. Draelos ZD, Matsubara A, Smiles K. The effect of 2% niacinamide on facial sebum production. J Cosmet Laser Ther. 2006;8(2):96\u2013101.<\/p>\n

7. Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DK. Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol. 1995;34(6):434\u2013437.<\/p>\n

8. Navarrete-Sol\u00eds J, et al. A double-blind, randomized clinical trial of niacinamide 4% versus hydroquinone 4% in the treatment of melasma. Dermatol Res Pract. 2011;2011:379173.<\/p>\n

9. Soma Y, et al. Moisturizing effects of topical nicotinamide on atopic dry skin. Int J Dermatol. 2005;44(3):197\u2013202.<\/p>\n

10. Draelos ZD, Ertel K, Berge C. Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. Cutis. 2005;76(2):135\u2013141.<\/p>\n

11. Gehring W. Nicotinic acid\/niacinamide and the skin. J Cosmet Dermatol. 2004;3(2):88\u201393.<\/p>\n

12. Wohlrab J, Kreft D. Niacinamide \u2014 mechanisms of action and its topical use in dermatology. Skin Pharmacol Physiol. 2014;27(6):311\u2013315.<\/p>\n

13. Boo YC. Mechanistic basis and clinical evidence for the applications of nicotinamide (niacinamide) to control skin aging and pigmentation. Antioxidants. 2021;10(8):1315.<\/p>\n

14. Bierman JC, et al. Niacinamide mitigates SASP-related inflammation induced by environmental stressors in human epidermal keratinocytes and skin. Int J Cosmet Sci. 2020;42(5):501\u2013511.<\/p>\n

15. Honeywell-Nguyen PL, Bouwstra JA. Vesicles as a tool for transdermal and dermal delivery. Drug Discov Today Technol. 2005;2(1):67\u201374.<\/p>\n

16. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Deliv Rev. 2002;54(Suppl 1):S41\u2013S55.<\/p>\n

17. Verma DD, Verma S, Blume G, Fahr A. Particle size of liposomes influences dermal delivery of substances into skin. Int J Pharm. 2003;258(1\u20132):141\u2013151.<\/p>\n

18. Lademann J, et al. Nanoparticles \u2014 an efficient carrier for drug delivery into the hair follicles. Eur J Pharm Biopharm. 2007;66(2):159\u2013164.<\/p>\n

19. Vogt A, et al. 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol. 2006;126(6):1316\u20131322.<\/p>\n

20. Choi YH, Shin JY, Kim J, Kang NG, Lee S. Niacinamide down-regulates the expression of DKK-1 and protects cells from oxidative stress in cultured human dermal papilla cells. Clin Cosmet Investig Dermatol. 2021;14:1519\u20131528.<\/p>\n

21. Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of niacinamide and niacin. Int J Toxicol. 2005;24(Suppl 5):1\u201331.<\/p>\n

Image credits \u2014 vesicle schematic, confocal micrographs, follicular-targeting schematics \u2014 PuriPharm technical library (company archive).<\/p>\n","protected":false},"excerpt":{"rendered":"

01 \u00b7 THE STARTING POINT The niacinamide paradox Powerfu […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[25],"tags":[],"_links":{"self":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1425"}],"collection":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1425"}],"version-history":[{"count":2,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1425\/revisions"}],"predecessor-version":[{"id":1427,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=\/wp\/v2\/posts\/1425\/revisions\/1427"}],"wp:attachment":[{"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1425"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.puriactives.com\/en\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}